{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T15:10:34Z","timestamp":1794496234769,"version":"4.9.1"},"reference-count":89,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.autrev.2025.103922","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T15:23:20Z","timestamp":1756221800000},"page":"103922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Updated systematic literature review and meta-analysis to inform the Italian Society of Rheumatology Recommendations on the treatment of rheumatoid arthritis-associated interstitial lung disease"],"prefix":"10.1016","volume":"24","author":[{"given":"A.","family":"Fassio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Pollastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Cozzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Crotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ughi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"De Lorenzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Radin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Landolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Rozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Manfredi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2025.103922_bb0005","first-page":"819","article-title":"Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study","volume":"23","author":"Salaffi","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0010","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00296-014-2974-6","article-title":"Prevalence and incidence of rheumatoid arthritis in Italy","volume":"34","author":"Rossini","year":"2014","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.autrev.2025.103922_bb0015","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/MCP.0000000000000710","article-title":"Recent advances in rheumatoid arthritis-associated interstitial lung disease","volume":"26","author":"Juge","year":"2020","journal-title":"Curr. Opin. Pulm. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0020","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1002\/acr.24856","article-title":"Incidence, risk factors, and mortality of clinical and subclinical rheumatoid arthritis-associated interstitial lung disease: a population-based cohort","volume":"74","author":"Samhouri","year":"2022","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2025.103922_bb0025","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3899\/jrheum.171315","article-title":"Rheumatoid arthritis-interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality","volume":"46","author":"Raimundo","year":"2019","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0030","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.reuma.2022.03.005","article-title":"SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: Treatment","volume":"18","author":"Narv\u00e1ez","year":"2022","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"10.1016\/j.autrev.2025.103922_bb0035","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of CHEST Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.autrev.2025.103922_bb0040","series-title":"Le raccomandazioni della Societ\u00e0 Italiana di Reumatologia sul trattamento del paziente con artrite reumatoide e interstiziopatia polmonare","year":"2024"},{"key":"10.1016\/j.autrev.2025.103922_bb0045","author":"Interstitial Lung Disease Clinical Practice Guidelines"},{"key":"10.1016\/j.autrev.2025.103922_bb0050","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.autrev.2025.103922_bb0055","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2025.103922_bb0060","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.autrev.2025.103922_bb0065","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jclinepi.2007.08.005","article-title":"Identifying phases of investigation helps planning, appraising, and applying the results of explanatory prognosis studies","volume":"61","author":"Hayden","year":"2008","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.autrev.2025.103922_bb0070","author":"Serious Adverse Reaction"},{"key":"10.1016\/j.autrev.2025.103922_bb0075","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0080","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1007\/s10067-023-06623-7","article-title":"Effect of nintedanib in patients with progressive pulmonary fibrosis associated with rheumatoid arthritis: data from the INBUILD trial","volume":"42","author":"Matteson","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0090","article-title":"Antifibrotics in the Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease: prospective real-world experience from an interstitial lung disease Clinic in India","volume":"16","author":"Behera","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.autrev.2025.103922_bb0095","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1093\/rheumatology\/kead027","article-title":"Lung function trajectory of rheumatoid arthritis\u2013associated interstitial lung disease","volume":"62","author":"Chang","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103922_bb0100","doi-asserted-by":"crossref","first-page":"182","DOI":"10.63032\/POPM9413","article-title":"Antifibrotics in rheumatoid arthritis-associated interstitial lung disease - real-world data from a nationwide cohort","volume":"3","author":"Duarte","year":"2024","journal-title":"ARP Rheumatol"},{"key":"10.1016\/j.autrev.2025.103922_bb0105","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.chest.2022.11.035","article-title":"Treatment outcomes for rheumatoid arthritis-associated interstitial lung disease: a real-world, multisite study of the impact of immunosuppression on pulmonary function trajectory","volume":"163","author":"Matson","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.autrev.2025.103922_bb0110","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13075-025-03491-1","article-title":"Long-term outcome of a treat-to-target strategy in late-onset rheumatoid arthritis with chronic lung disease: 5-year results of a prospective observational study","volume":"27","author":"Nomura","year":"2025","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103922_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003789","article-title":"Impact of DMARD treatment and systemic inflammation on all-cause mortality in patients with rheumatoid arthritis and interstitial lung disease: a cohort study from the German RABBIT register","volume":"10","author":"Rudi","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103922_bb0120","article-title":"The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study","volume":"9","author":"Wang","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0125","first-page":"10","article-title":"Predictors of progression and mortality in patients with prevalent rheumatoid arthritis and interstitial lung disease: a prospective cohort study","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0130","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/rheumatology\/keac651","article-title":"Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease","volume":"62","author":"Kim","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103922_bb0135","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221135314","article-title":"Protective effect of methotrexate on lung function and mortality in rheumatoid arthritis-related interstitial lung disease: a retrospective cohort study","volume":"16","author":"Kim","year":"2022","journal-title":"Ther. Adv. Respir. Dis."},{"key":"10.1016\/j.autrev.2025.103922_bb0140","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s10067-020-05227-9","article-title":"Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis","volume":"40","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0145","first-page":"10","article-title":"Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.autrev.2025.103922_bb0150","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/mr\/roac115","article-title":"Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: an ANSWER cohort study","volume":"33","author":"Makino","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0155","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/1756-185X.13434","article-title":"Association between chest computed tomography findings and respiratory adverse events in rheumatoid arthritis patients undergoing long-term biological therapy","volume":"22","author":"Matsumoto","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.autrev.2025.103922_bb0160","article-title":"Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia","volume":"63","author":"Matteson","year":"2011","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.autrev.2025.103922_bb0165","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00296-016-3478-3","article-title":"Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: a retrospective, case-control study","volume":"36","author":"Akiyama","year":"2016","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.autrev.2025.103922_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152710","article-title":"Real-world evidence of the antifibrotic nintedanib in rheumatoid arthritis-interstitial lung disease. National multicenter study of 74 patients","volume":"72","author":"Atienza-Mateo","year":"2025","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.autrev.2025.103922_bb0175","first-page":"9","article-title":"Rituximab in the treatment of interstitial lung disease associated with autoimmune diseases: experience from a single referral Center and literature review","author":"Atienza-Mateo","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0180","article-title":"Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis","author":"Atienza-Mateo","year":"2023","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.autrev.2025.103922_bb0185","first-page":"9","article-title":"Safety of abatacept in Italian patients with rheumatoid arthritis and interstitial lung disease: a multicenter retrospective study","author":"Cassone","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1265355","article-title":"Progression of radiographic fibrosis in rheumatoid arthritis-associated interstitial lung disease","volume":"10","author":"Chai","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0195","first-page":"296","article-title":"Rituximab for the treatment of connective tissue diseaseassociated interstitial lung disease","volume":"32","author":"Chartrand","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2025.103922_bb0200","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00296-021-04835-1","article-title":"A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease","volume":"41","author":"Cronin","year":"2021","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.autrev.2025.103922_bb0205","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor \u03b1 agents, a retrospective cohort study","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103922_bb0210","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1136\/ard.2009.120626","article-title":"Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology biologics register","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2025.103922_bb0215","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kex062.199","article-title":"Mortality in patients with rheumatoid arthritis and interstitial lung disease treated with tumour necrosis factor inhibitor or rituximab","volume":"56","author":"Druce","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103922_bb0220","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/03009742.2024.2371658","article-title":"Prognostic factors for interstitial lung disease progression in rheumatoid arthritis: May methotrexate protect against progression?","volume":"53","author":"Ekici","year":"2024","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0225","article-title":"Rituximab experience from a single Centre for patients with rheumatoid arthritis-related interstitial lung disease","volume":"39","author":"Sahin Eroglu","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.autrev.2025.103922_bb0230","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3899\/jrheum.121043","article-title":"Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease","volume":"40","author":"Fischer","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0235","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/imj.14306","article-title":"Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis","volume":"50","author":"Fui","year":"2020","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.autrev.2025.103922_bb0240","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1093\/rheumatology\/keaa608","article-title":"Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: clinical features and prognosis","volume":"60","author":"Izuka","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103922_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152312","article-title":"Effectiveness and tolerability of antifibrotics in rheumatoid arthritis-associated interstitial lung disease","volume":"64","author":"Juge","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"issue":"11","key":"10.1016\/j.autrev.2025.103922_bb0250","first-page":"2071","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data","volume":"40","author":"Kalyoncu","year":"2022","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0255","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1093\/rheumatology\/keaa577","article-title":"Rheumatoid arthritis related interstitial lung disease \u2013 improving outcomes over 25 years: a large multicentre UK study","volume":"60","author":"Kelly","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2025.103922_bb0260","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3904\/kjim.2015.30.1.104","article-title":"Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent","volume":"30","author":"Koo","year":"2015","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.autrev.2025.103922_bb0265","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.2169\/internalmedicine.2226-18","article-title":"Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis","volume":"58","author":"Kurata","year":"2019","journal-title":"Intern. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0270","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1501146","article-title":"Impact of Janus kinase inhibitors and methotrexate on interstitial lung disease in rheumatoid arthritis patients","volume":"15","author":"Kurushima","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.autrev.2025.103922_bb0275","doi-asserted-by":"crossref","first-page":"855","DOI":"10.3904\/kjim.2023.207","article-title":"Effect of abatacept versus conventional synthetic disease modifying anti-rheumatic drugs on rheumatoid arthritis-associated interstitial lung disease","volume":"39","author":"Lee","year":"2024","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.autrev.2025.103922_bb0280","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/1756-185X.14351","article-title":"Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: a single-center retrospective study from China","volume":"25","author":"Liu","year":"2022","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.autrev.2025.103922_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152517","article-title":"Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients","volume":"68","author":"L\u00f3pez-Maraver","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.autrev.2025.103922_bb0290","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern. Med. J."},{"key":"10.1016\/j.autrev.2025.103922_bb0295","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.21037\/jtd-22-1820","article-title":"Treatment of rheumatoid arthritis-associated interstitial lung disease in a multi-center registry cohort","volume":"15","author":"Marcoux","year":"2023","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.autrev.2025.103922_bb0300","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years\u2019 experience at a single Centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103922_bb0305","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14397595.2018.1481566","article-title":"Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept","volume":"29","author":"Mochizuki","year":"2019","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0310","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1093\/mrcr\/rxad021","article-title":"Combination treatment with Janus kinase inhibitor and nintedanib for rheumatoid arthritis with progressive interstitial lung disease: a case report","volume":"7","author":"Mochizuki","year":"2023","journal-title":"Mod Rheumatol Case Rep"},{"key":"10.1016\/j.autrev.2025.103922_bb0315","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open"},{"key":"10.1016\/j.autrev.2025.103922_bb0320","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3390\/diagnostics11101794","article-title":"Characteristics and predictors of progression interstitial lung disease in rheumatoid arthritis compared with other autoimmune disease: a retrospective cohort study","volume":"11","author":"Mena-V\u00e1zquez","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.autrev.2025.103922_bb0325","doi-asserted-by":"crossref","first-page":"7074","DOI":"10.3390\/jcm13237074","article-title":"Real-world clinical effectiveness and safety of antifibrotics in progressive pulmonary fibrosis associated with rheumatoid arthritis","volume":"13","author":"Narv\u00e1ez","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0330","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.reuma.2011.12.008","article-title":"Interstitial lung disease related to rheumatoid arthritis: evolution after treatment","volume":"8","author":"Rojas-Serrano","year":"2012","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"key":"10.1016\/j.autrev.2025.103922_bb0335","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","article-title":"Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis","volume":"36","author":"Rojas-Serrano","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0340","doi-asserted-by":"crossref","first-page":"7041","DOI":"10.3390\/jcm12227041","article-title":"Fibrosing progressive interstitial lung disease in rheumatoid arthritis: a multicentre Italian study","volume":"12","author":"Sebastiani","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0345","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.2024-0976","article-title":"Nintedanib in rheumatoid arthritis-related interstitial lung disease: real-world safety profile and risk of side effects and discontinuation","author":"Sebastiani","year":"2025","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0350","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1111\/1756-185X.14808","article-title":"The additional treatment value of immunoglobulin for the treatment of rheumatoid arthritis complicated with interstitial lung disease: a propensity score-matched pilot study","volume":"26","author":"Shen","year":"2023","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.autrev.2025.103922_bb0355","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.3390\/jcm13195871","article-title":"The therapeutic efficacy of abatacept for rheumatoid arthritis-associated interstitial lung disease: insights from a 12-month trial using semi-quantitative chest high-resolution computed tomography imaging","volume":"13","author":"Shoda","year":"2024","journal-title":"JCM"},{"key":"10.1016\/j.autrev.2025.103922_bb0360","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/pc2kq1","article-title":"Long-term efficacy of sarilumab on the progression of interstitial lung disease in rheumatoid arthritis: the KEIO-RA cohort and literature review","author":"Suzuki","year":"2024","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0365","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1007\/s10067-021-05854-w","article-title":"Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression","volume":"40","author":"Tardella","year":"2021","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0370","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.autrev.2025.103922_bb0375","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s11845-024-03848-6","article-title":"Nintedanib and its combination with immunosuppressives in connective tissue disease-related interstitial lung diseases","volume":"194","author":"Tekgoz","year":"2025","journal-title":"Ir. J. Med. Sci."},{"key":"10.1016\/j.autrev.2025.103922_bb0380","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41927-024-00374-x","article-title":"Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: a retrospective nested case-control study","volume":"8","author":"Tsujii","year":"2024","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.autrev.2025.103922_bb0385","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1007\/s10067-024-07028-w","article-title":"Forced vital capacity trajectories and risk of lung transplant and ILD-related mortality among patients with rheumatoid arthritis-associated interstitial lung disease","volume":"43","author":"Venkat","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0390","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/03009740601153774","article-title":"Rheumatoid arthritis treatment and the risk of severe interstitial lung disease","volume":"36","author":"Wolfe","year":"2007","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.autrev.2025.103922_bb0395","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/resp.13365","article-title":"Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus","volume":"23","author":"Yamano","year":"2018","journal-title":"Respirology"},{"key":"10.1016\/j.autrev.2025.103922_bb0400","first-page":"12","article-title":"Evolution of rheumatoid-arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a retrospective exploratory study","author":"Venerito","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.autrev.2025.103922_bb0405","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2025.103922_bb0410","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000473","article-title":"Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic","volume":"3","author":"Druce","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2025.103922_bb0415","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.semarthrit.2020.08.008","article-title":"Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease","volume":"50","author":"Narv\u00e1ez","year":"2020","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.autrev.2025.103922_bb0420","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2665-9913(24)00265-0","article-title":"Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study","volume":"7","author":"England","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.autrev.2025.103922_bb0425","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/diagnostics13071221","article-title":"Efficacy and safety of Nintedanib in patients with connective tissue disease-interstitial lung disease (CTD-ILD): a real-world single Center experience","volume":"13","author":"Boutel","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.autrev.2025.103922_bb0430","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1136\/annrheumdis-2020-eular.1630","article-title":"Abatacept in combination with metotrexate in patients with rheumatoid arthritis associated to interstitial lung disease: national multicenter study of 263 patients","volume":"79","author":"Fernandez-Diaz","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.autrev.2025.103922_bb0435","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40744-021-00396-8","article-title":"Fine comparison of the efficacy and safety between GB242 and infliximab in patients with rheumatoid arthritis: a phase III study","volume":"9","author":"Liu","year":"2022","journal-title":"Rheumatology and Therapy"},{"key":"10.1016\/j.autrev.2025.103922_bb0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2025.103804","article-title":"Efficacy, safety, and tolerability of antifibrotic agents in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"24","author":"Narv\u00e1ez","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.autrev.2025.103922_bb0445","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.resinv.2023.02.007","article-title":"Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept or JAK inhibitors for 1 year","volume":"61","author":"Mochizuki","year":"2023","journal-title":"Respir. Investig."}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001831?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997225001831?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T12:27:13Z","timestamp":1765024033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997225001831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":89,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1568997225001831"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103922","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated systematic literature review and meta-analysis to inform the Italian Society of Rheumatology Recommendations on the treatment of rheumatoid arthritis-associated interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103922","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103922"}}